The direct oral anticoagulant (DOAC) edoxaban is a potential alternative mode of thromboprophylaxis in children with cardiac disease showing low rates of clinically relevant bleeding (CRB) and thromboembolism (TE), with advantages of once-daily dosing and infrequent monitoring requirement versus standard of care, according to new data from the ENNOBLE-ATE trial.